MedWatch

Zealand Pharma planned for success

Despite great progress of its clinical pipeline and the initiation of two phase III studies, the Danish biotech company Zealand Pharma maintains its guidance for the level of costs in 2017. “We planned for success from the beginning of the year,” says CEO Britt Meelby Jensen.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

2017 var et rekordår for kapitalrejsninger i Skandinavien

Skandinaviske life science-selskaber rejste ligeså mange penge i 2017 som i de tre foregående år tilsammen, viser en ny rapport fra svenske Industrifonden. Sverige førte ikke overraskende an, men der var også fremgang at spore i Danmark og Norge.

Related articles